Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Oncovin
gptkb:anaplastic_lymphoma |
| gptkbp:appointed_by |
hospital settings
intravenous infusion outpatient settings |
| gptkbp:associated_with |
immunosuppression
|
| gptkbp:based_on |
dose-dense chemotherapy
|
| gptkbp:can_lead_to |
secondary malignancies
|
| gptkbp:consists_of |
gptkb:Cyclophosphamide
gptkb:Doxorubicin gptkb:Prednisone gptkb:Vincristine |
| gptkbp:developed_by |
lymphoproliferative disorders
Dr. John A. Chan |
| gptkbp:first_introduced |
1970s
|
| gptkbp:has_variants |
CHOP-14
CHOP-R |
| https://www.w3.org/2000/01/rdf-schema#label |
CHOP regimen
|
| gptkbp:is_associated_with |
gptkb:fandom
thrombocytopenia neutropenia |
| gptkbp:is_compared_to |
other chemotherapy regimens
|
| gptkbp:is_considered |
first-line treatment
a cornerstone of lymphoma treatment effective in elderly patients effective in young patients |
| gptkbp:is_effective_against |
aggressive lymphomas
|
| gptkbp:is_evaluated_by |
quality of life
clinical trials survival rates long-term outcomes |
| gptkbp:is_monitored_by |
gptkb:hospital
|
| gptkbp:is_often_associated_with |
gptkb:Rituximab
|
| gptkbp:is_part_of |
multimodal treatment approach
NCCN guidelines combination chemotherapy |
| gptkbp:is_studied_in |
safety
efficacy tolerability |
| gptkbp:is_used_for |
gptkb:healthcare_organization
gptkb:Non-Hodgkin_lymphoma |
| gptkbp:is_used_in |
clinical practice
pediatric oncology adult oncology |
| gptkbp:precedes |
growth factors
antiemetics |
| gptkbp:requires |
gptkb:battle
|
| gptkbp:side_effect |
fatigue
nausea hair loss low blood cell counts |
| gptkbp:suitable_for |
gptkb:ASCO
pregnant women severe liver disease patients severe heart disease patients |
| gptkbp:treatment |
6 to 8 cycles
|
| gptkbp:type_of_care |
certain lymphomas
|